English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Original Research Article The Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney Foundation (NKF) established a definition and classification of CKD in 2002. Kidney disease is the ninth leading cause of death in the United States. Coronary artery disease (CAD) is the major cause of death in patients with chronic kidney disease (CKD), responsible for up to 45% of overall mortality. The biochemical diagnosis of myocardial infarction in patients with CKD is always complicated by the fact that serum markers of myocardial necrosis such as creatine kinase, MB-fraction of creatine kinase. (CK-MB) are commonly increased in end stage CKD patients, even in the absence of clinically suspected myocardial infarction. Cardiac troponin (cTn) is a component of the contractile apparatus of the cardiac muscle. Because of its high tissue specificity, cTn is a cardio-specific, highly sensitive marker of myocardial damage. However, increases in serum cTn concentration have been reported in patients with CKD in the absence of acute myocardial infarction. Various study suggest that Elevations of cTnI not associated with ACS were common in patients with CKD stage 3 to 5, and there was an increase in mortality with higher concentrations of cTnI. Objective: To assess the elevated level of cardiac troponin in patients of Chronic kidney Disease stage 3 to above, on and off Haemodialysis. Mateial and Method: Cross sectional analytical study was carried out in our instituation for duration of 1year.Total of 100 subjects was enrolled in the study. Result: High cardiac Troponin level (>.1ng/ml) was associated with advanced stage or increased severity of disease. Conclusion: We concluded that higher Troponin value is more associated with higher stage of CKD and disease severity and also associated with increased age due to decreased GFR in advancing age but not significantly affected by co-morbid condition so every CKD patient should be tested for cardiac Troponin to identify the severity of disease.

A Study on Elevated Level of Cardiac Troponin in Patients of Chronic Kidney Disease Stage 3 to above, on and off Haemodialysis